MSD Portugal

Name

MSD Portugal

Legal name

Merck Sharp & Dohme, Lda.

Website

https://msd.pt

Company type

Private

Founded year

1970

Operating status

Operating

Headcount range

101–250 employees

Ownership category

akta.pro rank

Product category

Pharmaceuticals

NAICS

Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414), Drugs and Druggists' Sundries Merchant Wholesalers (4242)

SIC

Pharmaceutical Preparations (2834), Biological Products, (No Disgnostic Substances) (2836)

akta.pro industry

PRIMARYHLAIAAAB

Specialty Care Pharmaceuticals

Healthcare & Life Sciences/Pharmaceuticals/Branded (Innovator) Pharmaceuticals

Keywords

• Prescription pharmaceuticals
• Vaccines distribution
• Oncology therapeutics
• Antiretroviral medicines
• Diabetes therapeutics

Headquarters

HQ city

Paço de Arcos, Oeiras

HQ country

Portugal

HQ region

Europe

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Marketing or Sales, Operations, Technology or R&D, Infrastructure

Revenue model

1. Pharmaceutical product sales: MSD Portugal generates revenue through the sale of prescription medicines, vaccines, and hospital products across therapeutic areas including oncology, vaccines, infectious diseases, diabetes, and pulmonary hypertension. Revenue is derived from sales to healthcare providers, hospitals, pharmacies, and public health systems in Portugal.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels7 records

Core offering

MSD Portugal commercializes and distributes prescription medicines and vaccines across multiple therapeutic areas — oncology, vaccines, infectious diseases (HIV, antibiotics, antifungals, antivirals), diabetes, pulmonary hypertension, and chronic cough — selling to hospitals, clinics, retail pharmacies, and the Portuguese National Health Service (SNS), with reimbursement set by INFARMED. The portfolio is built on proprietary molecules developed by parent Merck & Co. and includes flagship brands such as Keytruda, Gardasil 9, Januvia, Isentress, Cubicin, Adempas, and Lynparza.

Product overview

MSD Portugal operates as the Portuguese subsidiary of Merck & Co., offering a diverse portfolio of prescription pharmaceuticals across multiple therapeutic areas. The product portfolio spans vaccines (including pneumococcal vaccines CAPVAXIVE, PNEUMOVAX 23, VAXNEUVANCE, HPV vaccine GARDASIL 9, MMR vaccine M-M-RVAXPRO, rotavirus vaccine ROTATEQ, hepatitis A vaccine VAQTA, varicella vaccine VARIVAX, and hexavalent vaccine VAXELIS), oncology treatments (KEYTRUDA, LYNPARZA, TEMODAL, ONCOTICE, WELIREG), antidiabetic medications (JANUVIA, JANUMET, XELEVIA, VELMETIA, EFFICIB, STEGLATRO, SEGLUROMET), antiretroviral/HIV medications (ISENTRESS, DELSTRIGO, PIFELTRO), antibiotics (CUBICIN, INVANZ, RECARBRIO, ZERBAXA), antifungals (NOXAFIL), antivirals (PREVYMIS), pulmonary hypertension treatments (ADEMPAS, WINREVAIR), respiratory treatments (LYFNUA for chronic cough), and other specialty medications. The portfolio is organized by therapeutic areas: Cardiovascular, Diabetes, Infectious Diseases, Oncology, Chronic Cough, and Vaccines.

Differentiator

Problem solved

Functional benefit

Products and services

• Keytruda (Pembrolizumab) PD-1 inhibitor (pembrolizumab 25mg/ml powder for concentrate for solution for infusion) for oncology treatment across multiple cancer types, prescribed by oncologists in Portuguese hospitals.
• Gardasil 9
• Januvia (Sitagliptin)
• Janumet (Sitagliptin + Metformin)
• Steglatro (Ertugliflozin)
• Segluromet (Ertugliflozin + Metformin)
• Isentress (Raltegravir)
• Pifeltro (Doravirine)
• Delstrigo (Doravirine/Lamivudine/Tenofovir disoproxil fumarate)
• Capvaxive
• Vaxneuvance
• Pneumovax 23
• Rotateq
• M-M-Rvaxpro
• Vaqta
• Varivax
• Vaxelis
• Lynparza (Olaparib)
• Temodal (Temozolomide)
• Oncotice
• Welireg (Belzutifan)
• Cubicin (Daptomycin)
• Invanz (Ertapenem)
• Recarbrio (Imipenem/Cilastatin/Relebactam)
• Zerbaxa (Ceftolozane + Tazobactam)
• Noxafil (Posaconazole)
• Prevymis (Letermovir)
• Adempas (Riociguat)
• Winrevair (Sotatercept)
• Lyfnua (Gefapixant)

Quantifiable outcome

• 154 million lives saved by essential vaccines over the past 50 years (6 lives saved per minute)
• +2 more outcomes

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Four partnerships are on record, tiered supporting and core.

• HPV Portugal (hpv.pt)supportingGTM or Marketing PartnerMSD Portugal has established a partnership with hpv.pt, a platform dedicated to HPV (Human Papillomavirus) awareness and education. MSD supports this initiative as part of its health literacy strategy, providing information and resources on HPV prevention and vaccination to the Portuguese public and healthcare professionals. The partnership appears on the MSD Portugal Literacia em Saúde (Health Literacy) page under 'Parcerias' (Partnerships).
• Profissionais de SaúdecoreGTM or Marketing PartnerMSD Portugal operates profissionaisdesaude.pt, a dedicated portal for healthcare professionals, providing access to clinical information, product details, prescribing information, and medical resources. This platform serves as a key channel for reaching and engaging healthcare professionals in Portugal. It is listed under MSD Portugal's health literacy initiatives.
• Clic@MSDcoreGTM or Marketing PartnerMSD Portugal operates clicamsd.pt, a digital service platform for healthcare professionals. This platform provides product information, medical resources, and support tools for healthcare professionals. It is part of MSD's digital strategy to engage and serve the healthcare professional community.
• Patient Organizations in PortugalsupportingStrategic or Co-development PartnerMSD Portugal supports patient organizations operating in Portugal through financial and scientific collaboration. In 2025, MSD supported multiple patient associations through initiatives aligned with its corporate responsibility programme. The list of supported organizations is published annually in MSD's transparency report (Relatório de Transparência). This partnership supports disease awareness, patient support, and health literacy objectives.

Scale indicators3 records

Recent moves6 records

Expansion highlights4 records

Direct peers

• Novartis Portugal: Portuguese subsidiary of Novartis, with overlapping portfolios in oncology, cardiology, and specialty medicines, competing for the same hospital, SNS, and physician-prescriber channels as MSD Portugal.
• AstraZeneca Portugal: Portuguese subsidiary of AstraZeneca with overlapping oncology, respiratory, and cardiometabolic portfolios, competing with MSD Portugal for hospital, specialty, and primary-care channels in Portugal.
• Sanofi Portugal: Portuguese subsidiary of Sanofi, with comparable vaccines, diabetes, and specialty-care franchises (including Dupixent in respiratory/dermatology), competing with MSD Portugal across multiple therapeutic areas including vaccines, diabetes, and rare diseases.
• Johnson & Johnson Innovative Medicine Portugal: Portuguese subsidiary of J&J's pharmaceutical segment, competing with MSD Portugal in oncology, hematology, infectious diseases, and pulmonary hypertension (notably through competing PAH therapies).
• Bayer Portugal: Portuguese subsidiary of Bayer, which co-promotes ADEMPAS (riociguat) with MSD globally; Bayer Portugal competes in specialty cardiology and women's health and shares co-marketing economics on MSD's pulmonary hypertension franchise.
• Bristol-Myers Squibb Portugal: Portuguese subsidiary of BMS, with overlapping oncology and hematology portfolios (including PD-1 inhibitors Opdivo) and cardiovascular specialty products, competing head-to-head with MSD Portugal in hospital oncology channels.
• Pfizer Portugal: Portuguese subsidiary of Pfizer, one of the world's largest biopharmaceutical companies, with a comparable diversified prescription and vaccine portfolio across oncology, vaccines, infectious diseases, and primary care specialties, directly competing with MSD Portugal for hospital tenders, SNS reimbursement, and physician access.
• GSK Portugal: Portuguese subsidiary of GSK, a direct peer in vaccines (including pneumococcal and HPV franchises), HIV (ViiV), and specialty medicines, competing for the same SNS tender and vaccination-program contracts.
• AbbVie Portugal: Portuguese subsidiary of AbbVie, competing in immunology, oncology, and neuroscience, and increasingly in pneumococcal vaccines, creating direct overlap with MSD Portugal's specialty and vaccine portfolios.
• Roche Portugal: Portuguese subsidiary of Roche, a leading oncology-focused biopharma with strong hospital and specialty-care presence; competes directly with MSD Portugal in oncology (Keytruda vs. Roche's immuno-oncology and targeted therapy franchises) and shares the same hospital sales-led GTM motion.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• Xtwitter.com/msd_portugal
• LinkedInlinkedin.com/company/msdportugal
• Instagraminstagram.com/msd_weareinventors

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about MSD Portugal